Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
HSP90, a molecular chaperone, has been identified as a drug target in inflammatory skin diseases. However, 4 different HSP90 isoforms (HSP90α, HSP90β, GRP94, and TRAP1) exist. Therefore, this study aimed to evaluate the functional role of the HSP90 isoforms in skin inflammation. Selective knockdown of the HSP90 isoforms revealed different inflammatory effects in stimulated keratinocytes. TRAP1 knockdown significantly downregulated the expression of the measured inflammatory genes (IL1B, IL6, IL17C, IL23A, IL19, IL36G, CXCL8, CCL5, CCL17, CCL20). Selective and combined knockdown of HSP90α and HSP90β showed a trend toward increased inflammatory activity. Selective GRP94 knockdown and combined knockdown of the organelle-specific isoforms (GRP94 + TRAP1) or all 4 isoforms resulted in inconsistent effects. In addition, a selective TRAP1 inhibitor (gamitrinib) suppressed the inflammatory gene expression in keratinocytes and fibroblasts (IL17C, IL23A, IL36G) and in hidradenitis suppurativa skin cultured ex vivo (IL1B, IL6, CXCL8, IL17A, IL36G). In conclusion, selective and simultaneous knockdown of the HSP90 isoforms mediated different inflammatory effects, revealing that the HSP90 isoforms have distinct roles in skin inflammation. In addition, we discovered that inhibition of TRAP1 exerted consistent anti-inflammatory effects, suggesting that TRAP1 inhibitors may represent a topical therapeutic strategy for inflammatory skin diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2025.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TRAP1 and its therapeutic potential.
Bioorg Med Chem Lett
September 2025
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States. Electronic address:
The mitochondrial Hsp90 isoform, Tumor Necrosis Factor Receptor Associated Protein 1 (TRAP1), is central to the pathogenesis of disease states that include cancer, ischemic retinopathy, and diabetic kidney disease among others. TRAP1 contributes to these diseases through the regulation of mitochondrial metabolism, apoptosis, oxidative stress, cell signaling and angiogenesis through interactions with client proteins. Numerous TRAP1-selective inhibitors have been developed to limit the toxicities associated with Hsp90 pan-inhibition, while leveraging the therapeutic benefits of TRAP1 inhibition.
View Article and Find Full Text PDFPKD and scaffold NHERF1 mediate hypoxia-induced gene expression in 3T3-L1 adipocytes.
J Mol Endocrinol
August 2025
Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Hypoxia has been implicated as a causal factor in mediating adipocyte dysfunction in obesity. Moreover, protein kinase D 1 (PKD1), a serine/threonine protein kinase, has been shown to contribute to diet-induced adiposity. Therefore, we investigated if PKD isoforms mediate hypoxia-induced dysfunction in 3T3-L1 adipocytes.
View Article and Find Full Text PDFHsp90 and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy.
Pharmaceuticals (Basel)
July 2025
Department of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
The 90 kDa heat shock proteins (Hsp90) are molecular chaperones that regulate the stability and maturation of numerous client proteins implicated in the regulation of cancer hallmarks. Despite the potential of -Hsp90 inhibitors as anticancer therapeutics, their clinical development has been hindered by on-target toxicities, particularly ocular and cardiotoxic effects, as well as the induction of pro-survival, compensatory heat shock responses. Together, these and other complications have prompted the development of isoform-selective Hsp90 inhibitors.
View Article and Find Full Text PDFRecent advances in HSP90 inhibitors as targeted cancer therapy: Chemical scaffolds, isoform selectivity, and clinical progress.
Bioorg Chem
August 2025
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Changa 388421, India.
Heat shock protein 90 (HSP90) is an ATP-dependent chaperone essential for the proper folding, stabilization, and activation of numerous client proteins, many of which are implicated in oncogenic signaling pathways. Overexpressed in various cancers, HSP90 facilitates tumor growth, metastasis, and therapy resistance by stabilizing key oncoproteins such as HER2, AKT, RAF, and mutant p53, making it a compelling target for cancer therapeutics. Despite extensive research, pimitespib remains the only approved HSP90 inhibitor, while others like ganetespib (STA-9090) and onalespib (AT13387) are undergoing clinical trials with variable outcomes (varying efficacy and tolerability profiles).
View Article and Find Full Text PDFOptimization of an Hsp90β-selective inhibitor via exploration of the Hsp90 N-terminal ATP-binding pocket.
Eur J Med Chem
November 2025
Department of Chemistry and Biochemistry, Warren Family Research Center for Drug Discovery and Development, The University of Notre Dame, Notre Dame, IN, 46556, United States of America. Electronic address:
The 90-kDa heat shock protein (Hsp90) promotes the maturation of >400 client protein substrates, many of which are implicated in the development/progression of cancer. Although 22 Hsp90 N-terminal inhibitors have undergone clinical evaluation, the toxicities that arose from pan-inhibition have hindered their development as chemotherapeutic agents. Hence, Hsp90 isoform-selective inhibition represents a promising alternative to overcome these detriments.
View Article and Find Full Text PDF